PRE-FEASIBILITY REPORT

FOR TERMS OF REFERENCES

October, 2016

SRI KRISHNA PHARMACEUTICALS LIMITED

PLOT NO. F-1,
MIDC CHINCHOLI,
TALUKA- MOHOL,
SOLAPUR DISTRICT
MAHARASTRA

Studies & Documentation By

M/S Pridhvi Enviro Tech pvt. Ltd
Submitted by (MoE&F O.M – S.NO: 122, rev 46,
dated 5.10.2016)
Sri Krishna pharmaceuticals Ltd, 184/C, Lawn House
Plot No. F-1 Vengal Rao Nagar
MIDC, Chincholi Hyderabad-500038
Taluka Mohol Ph: 040-40179770
Solapur (D) Fax: 040-66730926
Maharastra E-Mail: pvr@pridhvienviro.com

SUBMITTED TO
MINISTRY OF ENVIRONMENT & FORESTS, GOI
PARYAVARAN BHAWAN, CGO COMPLEX,
LODHI ROAD, NEW DELHI-110003
 CONTENTS

S.No. Description Page No.

1 Introduction 1
2 Introduction of the project 2
Introduction of the company and the 3
proponent
3 Project Description 4
3.1 Production Capacity 4
3.2 Manufacturing Process 5
3.3 Raw materials 5
3.4 Water Requirement 5
3.5 Waste generation and control systems 6
3.5.1 Liquid effluents 6
3.5.2 Solid waste management 9
4 Site Analysis 10
4.1 Plant location 10
5 Planning in Brief 16
6 Resource requirement 16
6.1 Power requirement and Supply/ Source 16
6.2 Production facilities , Utilities and 16
effluent handling facilities
6.3 Land requirement 17
7 Air pollution 18
8 Bulk chemical storage 18
9 Base line data studies 19
10 Project financial 19
 LIST OF TABLES

Table No. Description Page No.

1.0 Salient Features of the Project 2
2.0 List of Proposed Products 4
3.0 Water Balance Proposed 5
4.0 Solid Waste and Disposal 9
5.0 Utilities /ETP-Proposed 16
6.0 Land Statement 17
7.0 Emission Source Proposed 18
8.0 Storage facilities of bulk chemicals 18

LIST OF FIGURES

Fig No Description Page No.

1.1 Schematic treatment scheme of high 7
TDS effluents
1.2 Low TDS Effluent Treatment System 8
1.3 Topo Map of the Study Area 12
1.4 Base Map of the Study Area 13
1.5 Photographs of current condition of the 14
site
1.6 Site layout plan 15

LIST OF ANNEXURES

Annexure Description
I Typical Technical details of proposed products
II List of Raw materials
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

1. Introduction

Sri Krishna Pharmaceuticals Ltd., engaged in manufacturing of Active

Pharmaceutical Ingredients, and Intermediates was established in the year
1975. Research and Development forms the backbone of the organization with
state of the art instrumentation facilities. They have Five manufacturing sites in
India four in Telangana manufacturing bulk drugs & formulations and one in
Maharastra manufacturing Drug intermediates .

Sri Krishna Pharmaceuticals limited proposed to establish a new unit at

Plot. No. F-1, MIDC, Chincholi, Taluka-Mohol, Sholapur District,
Maharastra state.

The unit obtained TOR for the proposed unit from SEAC, Maharastra and
submitted draft EIA Report based on Model TOR’s on April 5th 2014. The
proposed unit is located in Notified industrial Area, MIDC, Chincholi, As
the unit is within 5 KM from the proposed eco sensitive zone of the Nanaj
Sanctuary Great Indian Bustard sanctuary.

In the year 2014, Hon. Supreme Court had given directions to all State
Govts. to finalize the ESZs for all the PAs coming under them. Further,
directions were given by Hon. Supreme Court that in absence of finalized
ESZ or for a period till the ESZ gets finalized, a distance of 10 Km from
the boundary of PA would be treated as ESZ.

Under such circumstances, as per the provisions in MoEF notification

dated 14.09.2006, any project in Cat. B coming in ESZ of a Protected
Area would be treated as Cat. A and hence the State Level EIA Authority
rejected the case and advised the company to approach MOEF in Delhi for
the clearance

1
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Hence this application is made for obtaining fresh TOR. As the unit is
located in IE, Chincholi which is notified industrial area established prior
to 2006 notification, Public hearing may be exempted for this unit.

In order to meet the market demand it is now proposed to manufacture 6

API’s with a production capacity of 2545 TPM.

2. Introduction of the Project

The proposed unit is to manufacture Bulk Drugs (APIs) to a tune of 1250

TPA. The salient features of the project are described in the table given
below
TABLE 1.0

Salient Features of the Project

Location F-1, MIDC Chincholi (V), Mohol (Taluk),
Solapur (district), Maharashtra

Longitude and Latitude 17o46’20.9’’ N 75o 48’13.0’’ E

Product Category
Project Category as per EIA
notification
Proposed Activity
Total investment on the plant
Total Investment on
Environmental Infrastructure
Total area of the plant
Total area of green belt
Water requirement
Source of water
Nearest habitation and
distance from the site
Nearest surface water bodies
Nearest reserve forest
Environmentally sensitive
17o46’35.3’’ N 75o 48’12.9’’ E
17o46’35.2’’ N 75o 48’05.3’’ E
17o46’20.6’’ N 75o 48’05.5’’ E
5(F) Bulk Drugs & Intermediates
Category A (located within 5 Km distance
from the proposed ESZ of GIB Nanaj
Sanctuary)
Drugs & Drug intermediates- 2545 TPM
Rs. 125 Crores
Rs. 8 Crores
25.0 Acres
9.3 Acres
Total water requirement for project will be
1430 KLD.
Fresh water requirement- 973 KLD
Recycled water- 457 KLD
MIDC, Chincholi.
Chincholi Village-0.97 Km from the site (S)
Nanaj Odha is at a distance of 0.83 km from
the site
There are no reserve forests in 10 km radius
from the site
None
2
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

areas within 10 km radius

Any national parks, wild life
sanctuaries within 10 km
radius
Nearest air port and distance
Nearest railway station and
distance
National Highway
i) Introduction of the company and proponent
GIB Nanaj Sanctuary is at a distance of 7.68
Kms from the site.
Proposed ESZ of GIB Nanaj Sanctuary- 1.84
Kms
Solapur Airport- 21.3 km
Pakni Railway Station-5.76 km
NH 9 is at a distance of 3.1 Km from the
site

Sri Krishna Pharmaceuticals Ltd., engaged in manufacture, custom

manufacturing of Active Pharmaceutical Ingredients, and Intermediates was
established in the year 1975. Research and Development forms the backbone of
the organization with state of the art instrumentation facilities. They have four
manufacturing sites in India with a cumulative monthly production capacity of
200 TPM of chemical entities (APIs and APIs formulations about 710 TPM). Sri
Krishna have handled a wide spectrum of chemical unit processes significantly
being plant scale column chromatography, carbohydrate chemistry, natural
product extraction and other complex synthetic chemical reactions for high
purity compounds.

The company recognized the vital role of R & D for becoming successful in the
generic market. The proposed project under consideration would be located at
Plot No. F-1, MIDC, Chincholi, Taluka -Mohol, Dist. Solapur, State –Maharashtra.
state.
The company has Headquarter in Hyderabad, India, and is catering to the ever
growing demand of Active Pharmaceutical Ingredients (API’s) from single State-
of-the-art manufacturing facility. Already established unit in Chincholi MIDC
(Maharashtra) and has built up a reputation for excellence on the foundations of
consistent high quality, a constantly expanding product portfolio and timely
launches of new API’s.
The in-house QC Laboratories are equipped with sophisticated instruments to
assure the quality of the raw materials, intermediates and API’s. The company
believes in quality by design and continuous improvement in all aspects of its
operations. By this endeavor, Sri Krishna Pharma necessitates to recognize in
the global market of Pharmaceuticals as an important partner for API’s.

3
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

About Proponent
The management at Sri Krishna Pharmaceuticals Limited consists of highly
qualified and richly experienced persons who have given the company the edge
in terms of quality, consistency, timely delivery and ability.
The Group is headed by a technocrat with academic excellence. Dr. V.V. Subba
Reddy, Founder Chairman is a Post Graduate in Technology, Doctorate in
Science and a Post-Doctoral fellow from National Cancer Institute, NIH,
Maryland, USA. He also serves various trade associations, Government bodies
and Institutions as a representative of the pharmaceutical industry in India.
Quality Management: Strict quality control measures, Good Manufacturing
Practices (GMP) are integrated throughout the manufacturing process to ensure
strict adherence to the quality parameters for both in-process and finished
products.
3. Project Description

3.1 Production Capacity

SKPL intends to manufacture 2545 TPM of API (Bulk Drug & Intermediates)
products. Product wise capacity is given below:
TABLE 2.0
PROPOSED PRODUCTS & CAPACITY

Quantity
S.No Name of the Products Remarks
in TPM
400 Starting from PNCB -4
1A Paracetamol- 4 stages
Stages
1100 Starting from Penultimate
1B Paracetamol – 2 stages
stage-2 Stages
2 Ibuprofen 500
3 Metformin 500
4 Domperidone 15
Dextromethorphan
5 20
Hydrobromide
6 Omega -3 10
Total 2545
By Product
Generates in the process
1 Acetic Acid 1788
and
sold to consumers
2 Soap 40.0

4
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

3.2 Manufacturing Process

Brief process description and process flow charts are given at Annexure I

3.3 Raw Materials

List of raw material product wise is given at Annexure II

3.4 Water Requirement

The water requirement for process, domestic, gardening, boiler feed & for
cooling water make up is about 1430.0 KLD. The source of water is already
available from existing water works of MIDC and the same is adequate and
satisfactory. The water balance for daily consumption is presented below.
TABLE 3.0
Water Balance–Proposed

S. Stream Water Waste Proposed Method

No requirement Water of Treatment and
in KLD discharge in Disposal
KLD
1 566.0 649.0 Stripper, MEE and
Process
ATFD
2 Washings 10.0 10.0 (Condensate to RO)
Stripper, MEE and
3 Laboratory 1.0 1.0 ATFD
washings (Condensate to RO)
4 Scrubbers 50.0 50.0
5 Boiler 201.0 20.0 ETP followed by RO
( RO Reject to MEE)
6 DM/Softener 3.0 3.0
7 Cooling & 510.0 51.0
Regeneration
8 Domestic 50.0 40.0 Sewage Treatment
Plant & reused for
gardening &
flushing’s
9 Gardening 39.0 -
Total 1430.0 824.0

5
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

3.5 Wastes generation and control systems

3.5.1 Liquid Effluents

As detailed in Table 3.0 waste water generation due to process, domestic,

scrubbers, boilers and other activities would be 824.0 KLD. The quantity of
process effluent from the proposed activity will be segregated as high TDS and
low TDS streams.

High TDS and High COD stream would be treated in stripper followed by
MEE and ATFD. The resultant sludge would be disposed to TSDF,
Hyderabad. The Low TDS stream would be treated along with MEE/ATFD
condensates in biological ETP followed by RO. The RO rejects would be fed
back to MEE. The Permeate from RO would be used for cooling tower
make up. Domestic effluents are treated in sewage treatment plant. Thus
the treatment system proposed is based on “Zero Liquid Discharge” (ZLD)
Concept.

The schematic diagrams of ETP proposed are given in Figure 1.1 and
Figure 1.2 below

6
 Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Fig 1.1
Schematic Treatment Scheme of High TDS Effluents

Effluent from
Process and Equalization Neutralization Settling Aq. Distillate to
Stripper
Cement Plant/TSDF Recovery
Tank Tank Tank
Washings,
Scrubber
RO Reject

To TSDF
Condensate to
MEE Biological
Treatment

ATFD
Condensate to Biological Treatment

Sludge to TSDF

7
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Fig 1.2 Low TDS Effluent Treatment System

Domestic effluent

Screen
Chamber
Effluents from utilities & MEE condensate

Screen Equalization Neutralization Clarifier Aeration Aeration Clarifier

Chamber Tank Tank 1 Tank1 Tank2 2

Holding
Tank

Sludge Holding
Tank
Sand
filter

Carbon
Filter Press Filter
Sludge to TSDF Sludge Cake

Ultra
Permeate for re-use RO
filtration

Rejects to MEE

8
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

3.5.2 Solid wastes management

Hazardous and non - hazardous wastes generated from the proposed

project are detailed below. Mode of disposal are also identified and listed.
Adequate storage of hazardous waste is ensured at the site

TABLE 4.0
Solid Wastes and Disposal

S. Schedule Quantity in
Type of waste Disposal
No No. TPM
Hazardous waste
1 ETP Sludge 34.3 30.0 CHWTSDF
MEE salts / ATFD
2511.0
2 salts and 34.3 CHWTSDF
inorganic residue
3 Spent carbon 28.2 47.5 CHWTSDF
Distillation
bottom Authorized cement
4 20.3 412.4
Residue/process Industries/ CHWTSDF
sludge
5 Spent solvents 28.5 52.0 CHWTSDF
Authorized cement
6 Iron sludge 28.1 580.0
Industries
Authorized recyclers/
7 Waste oil 5.1 0.2
CHWTSDF
Authorized recyclers/
8 oil from process 5.1 10.0
CHWTSDF
Send to E- waste
9 E- Waste - 0.240
Recycler
Return to supplier for
Used Lead acid
10 - 2 Nos. replacement in
batteries
exchange

Biodegradable waste
Composting and used
1 ETP Bio sludge - 12.9 as manure for
gardening

9
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Non Biodegradable waste

100.0
1 Waste paper - Sale
Kgs/month
Corrugated 500.0
2 - Sale
boxes Kgs/month
100.0
3 Broken glass - Sale
Kgs/month
Decontaminated 100.0
4 - Sale
used drums Kgs/month
Decontaminated 100.0
5 - Sale
HDPE Bags Kgs/month
6 Coal ash - 280.0 Sale

CHWTSDF facility at Ranjangaon which is at a distance of 200 Km from

the site has agreed to cater the solid waste from the proposed site.
Transport of Hazardous wastes to TSDF is done by the CHWTSDF. In case
other hazardous wastes, authorized recyclers will transport the wastes.

4. Site Analysis

4.1 Plant Location

M/S Sri Krishna Pharmaceuticals Limited, F-1, MIDC, Chincholi(V), Mohol
(T), Solapur(D), Maharastra state. The site is situated at the following
Latitudes and longitudes
17o46’20.9’’ N 75o 48’13.0’’ E
17o46’35.3’’ N 75o 48’12.9’’ E
17o46’35.2’’ N 75o 48’05.3’’ E
17o46’20.6’’ N 75o 48’05.5’’ E
The land area of the plant is 25.0 acres. The nearest habitation from the
site is Chincholi (V) at a distance of 0.97 km. The nearest railway station
located at Pakni 5.76 KM from the Plant. GIB Nanaj Sanctaury which is
ecologically sensitive area is at a distance of 7.68 Km from the site and
the proposed Eco sensitive zone of GIB Sanctuary is at a distance 1.84
Km from the site. There are no reserve forests in 10 Km radius

10
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Following are the surroundings of the site

North – MIDC Road and Tara Hydro laboratories
South –MIDC Road
East – Road followed by LR indust–ries
West - Open land and Challa Chlorides

Topo graphic features of the site and 10 KM study area and base map are
given at Fig 1.3 & 1.4.
Plant & Green Belt Photographs are given at Fig. 1.5
Site lay out map is given at Fig 1.6

11
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Fig 1.3
Topo Sheet of the 10 KM study area

12
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Fig 1.4
Base map of the study area

13
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Fig 1.5
Plant Photographs

14
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

Fig 1.6
Site Lay Out Plan

15
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

5.0 Planning in Brief

The project is envisaged to be completed by November 2017, and the

production shall be initiated thereon. Consultants are identified for
preparing the detailed project report.

6. Resource requirements
6.1 Power Requirement and Supply/Source

The total power requirement for this proposed project will be 6000 HP.
The required power connection is available from MSEDCL.

In case of emergency, backup of three nos. of DG sets of capacity 1000

KVA each are proposed with acoustic enclosure.

6.2 Production facilities, Utilities and effluent handling facilities

SKPL it is proposed to arrange the production facilities, utilities and

effluents treatment infrastructure with an investment of Rs.125.0 Crores.
The details are outlined in the below table

TABLE 7.0

Production facilities/Utilities/ETP –Proposed

Capacity/
S.NO Details No Proposed
Production facilities
1 Production Blocks Nos 5
2 Clean rooms Nos 1
3 Boiler (coal Fired) TPH 2 x15 & 1x10*
4 DG sets KVA 2 X 1000
5 Cooling tower TR 5000
3
6 Softener/DM plant M /hour 2.5
7 Fresh water RO Plant M3/hour 2.5
Effluent handling & treatment facilities
8 Collection tanks- KL 400
Storage
9 Neutralization tanks KL 10
10 Stripper, MEE, ATFD KLD 2 X 400
11 RO & Biological KLD 600
treatment
12 Sewage treatment plant KL 40

* 1 X 10 TPH Boiler is stand by boiler

16
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

6.3 Land Requirement

The unit is proposed to build the plant in 25 Acres of land and out of which
6.0 acres will be built up area and 9.3 acres of green belt will be
developed. Below table provides the land statement. Detailed site lay out
plan outlining proposed activities is given at Figure 1.6

Table 8.0
Land Statement
S.No Purpose Units Extent
1 Built up area Acres 6.0
2 Green belt Acres 9.3
3 Open area Acres 9.7
Total Acres 25.0

7.0 Air Pollution

The Proposed sources of air emissions from the plant are 15 TPH coal
fired Boilers two in number and 10 TPH boiler and 3 X 1000 KVA DG sets.
The process emissions containing Acetic acid & HCl are scrubbed with
caustic and scrubbed waste send to MEE. Below Table gives proposed
emission sources from the plant
Table 9.0
Emission Source Proposed

S.No Proposed Capacity Fuel Anticipated Control

emissions system
1 Process --- -- Acetic acid Scrubber
fumes, HCl
2 Boiler 15 TPH Coal Stack Ht 47
Stack (2 nos) SPM,SO2 meters,
&NOx cyclone &
Dust collector
3 Boiler 10 TPH Coal SPM,SO2 Stack Ht
Stack &NOx 41.5 m
cyclone &
Dust collector

4 DG sets 3 X 1000 HSD SPM,SO2 Stack height

KVA &NOx of 6.3 meters
& acoustic
enclosure
17
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

8.0 Bulk Chemical Storages:

Following bulk chemical storage facilities are proposed

Table No 10.0

Storage facilities of bulk chemicals

S.No Name of the Solvent MOC No Of Storage

Tanks Quantity

1 Isopropyl alcohol MS 1 20KL

2 Isobutyl Benzene MS 1 20KL

3 Isobutyl Acetophenone MS 1 20KL
4 Isopropyl Chloro MS 1 20KL
acetate
5 Acetone MS 1 20KL
6 O-Xylene MS 1 20KL
7 Toluene MS 2 40KL
8 Methanol MS 1 20KL
9 MIBK MS 1 20KL
10 Caustic Lye (48%) MS 2 50KL
11 Sulphuric Acid MS 1 25KL
12 Acetic anhydride Aluminum 4 100KL
13 HCl PP-FRP 2 50KL
14 Liquor ammonia 25% MS 1 25KL
15 Acetic acid SS 4 100KL
16 Ammonia-LIQ cylinders 1 25KL

9. Baseline data studies

We have a unit at B-14/2 in MIDC Chincholi which is in the same MIDC
of the proposed site for which baseline data has been collected during the

18
Pre-Feasibility Report Sri krishna Pharmaceuticals Limited, Plot No. F-1

period of April 2016 to June 2016 so we request you to kindly allow us to

consider the same data for current study.

10. Project Financial

The estimated cost of the proposed project is approximately 125 Crores.

Out of this Rs. 8.0 Crores will be for effluents treatment facilities and rest
for other process equipment and safety equipment

Project cost
Rs. In
Crores
Plant& machinery 50.0
Civil & Structural 20.0
Total 70.0
20% on plant &
Pipe lines & insulation machinery 14.0
10% on plant &
Electricals & instrumentation machinery 7.0
8% on plant &
Erection & commissioning & machinery and
painting structures 5.6
Safety & Environment 10.0
Furniture, fixtures, computers,
lighting etc 0.5
Total 107.10
Contingencies & pre-operative
expenses 17.5
Project cost say 125 Crores

19
 Annexure I
Typical technical details of the proposed products
PARACETAMOL
Process description and flow sheets

Brief manufacturing process of Paracetamol

Stage-1 (Hydrolysis)

Para Nitro Chloro Benzene is treated with aqueous sodium hydoexide at a temperature of 135-
140oC in an autoclave and neutralized with sulphuric acid to get Para Nito Phenol.

Stage- 2 (Reduction)

Para Nitro Phenol is reduced in boiling water under mild acidic condition with iron poweder
and acetic acid to get Para Amino Phenol,

Stage -3 (Acetylation)

Para Amino Phenol is condensed with Acetic Anhydride in aqueous medium to get
paracetamol and acetic acid.

Stage-4 (Purification)

Paracetamol technical is dissolved in hot water, treated with carbon, crystallized to get
Paracetamol with is dred, milled and packed in LDPE lined HDPE bags.
 CHEMICAL PATHWAY OF PARACETAMOL SYSNTHESIS

Stage I -P-Nitro Phenol:

Cl ONa

Step 1. + 2NaOH + NaCl + H2O

2 x 40 58.5 18

NO2
NO2
PNCB
157.5 161

ONa OH

Step 2. + 0.5 H2SO4 + 0.5 Na2SO4

0.5 x 142

NO2
NO2
161
139
Para Nitro Phenol
(PNP)

Sta ge -II - P-A m ino p h en o l:

OH
OH

7 + 18 Fe + 7H 2 O + 9FeO + 3Fe 3 O 4+ xC H C O O N a + xH O
3 2
xCH 3C O O H + xN aO H 82 18
18x55.84 7x18 60 40 6Fe 3 O 3 .5 (A v)
NO2 NH2 6 x 223.52
7 x 139 7 x 1 09
PNP Para Am ino Phenol
(PAP )
S T A G E I I I - P a r a c e t a m o l T e c h n ic a l

OH O OH

CH3 C
+ O + C H 3C O O H
CH3 C 60

NH2 O
109 102 NHCOCH3
151
PAP A c e tic A n h y d r id e P a r a c e ta m o l

S ta g e - IV - P a ra c e ta m o l P h a rm a

OH OH

A c t iv e C a r b o n
+ S pen t carbon
Ph arm a M L

NHCOCH3 NHCOCH3
 PARACETAMOL

PROCESS FLOW DIAGRAM

Hydrolysis
4-Nitrochlorobenzene
Caustic soda Lye Conversion of PNCB to Nitrophenol
Water (PNP)
Stage I

Sulphuric acid Neutralisation

Aq layer
PNP

Reduction
PAP ML / Water
Dilute Acetic acid Conversion of PNP to
Iron powder Aminophenol (PAP)
Caustic soda Lye

Filtration Stage II
candle filter Iron sludge

Hydros Cooling and Filtration

SMBS Pusher Centrifuge Aq layer
PAP PAP ML

Pharma ML
Acetylation
Acetic anhydride
Soda ash Conversion of 4-Aminophenol
EDTA (PAP) to Paracetamol technical
Hydros
SMBS
Stage III

Filtration
Pusher Centrifuge
Process water/Pharma ML
Acetaminophen Technical
Soda ash Carbon treatment
Activated carbon
Hydros
SMBS

Filtration through Leaf

filter and Polishing filter

Stage IV

Recrystallisation
(cooling)

Hydros Filtration through Pharma ML

Agitated Nutsche Filter
DM Water

Acetaminophen (Paracetamol) pharma (wet)

 Annexure II
List of Raw Materials
List of Raw Materials of Paracetamol (Starting
from PNCB)

Qty
S.No Name of raw material (Kgs/day)
1 PNCB 16062.7
2 Caustic Lye (48%) 8486.6
3 Sulphuric Acid 5998.5
4 Iron Powder 14476.4
5 Acetic Acid (20%) 6731.7
6 Acetic anhydride 10184.1
7 EDTA 13.3
8 Hydros 26.7
9 SMBS 13.3
10 Activated Corbon 120.0
Sodium Hydro Sulphite(Hydros)
11 13.3
12 Sodium Meta Bisulphite(SMBS) 13.3
13 Caustic flakes 93.3

List of Raw Materials of Paracetamol

(Starting from PAP)

Qty
S.No Name of raw material (Kgs/day)
1 PAP (1% ) moisture) 29218.0
2 Acetic anhydride 28008.2
3 EDTA 36.7
4 Hydros 73.3
5 SMBS 36.7
6 Activated Corbon 329.9
Sodium Hydro
7 Sulphite(Hydros) 36.7
Sodium Meta
8 Bisulphite(SMBS) 36.7
9 Caustic flakes 256.6
 List of Raw Materials of Metformin HCl

Qty
S.No Name of raw material (Kgs/day)
1 Dicyanodiamide 8866.7
2 Dimethylamino hydrochloride 9566.7
3 Dimethyl formamide 11700.0
4 Toluene 6200.0
5 Methanol 2833.3
6 Activated carbon 533.3
7 Methanol 22700.0
 List of Raw Materials of Domperidone
S.No Name of raw material Qty (Kgs/day)
1 Orthophenylene di amine(OPDA) 279.0
2 Methyl Aceto acetate(MAA) 299.5
3 Xylene 1196.0
4 Caustic lye 48 % 247.5
5 Carbon 18.5
6 Conc. HCl 30 % 368.5
7 1- bromo-3-chloro-propane 335.0
8 Toluene 1195.0
9 Potassium carbonate 315.0
10 Conc. HCl 30 % 320.0
11 Caustic lye 48 % 20.0
12 N- Methyl Piperidone 360.0
13 Ethyl chloro formate 480.0
14 CS Flakes 290.0
15 Toluene 1295.0
16 Methanol 505.0
17 Raney Nickel 10.0
18 Ammonia gas 75.0
19 Hydrogen 5.0
20 DCNB 515.0
21 K2 CO3 300.0
22 Toluene 860.0
23 Potassium carbonate 150.0
24 Potssium chloride 160.0
25 Toluene 1435.0
26 Methanol 860.0
27 Raney Nickel 35.0
28 Hydrogen 15.0
29 Urea 255.0
30 Caustic lye 47 % 820.0
31 Ammonium chloride 575.0
32 Carbon 5.0
33 Conc. HCl 30 % 210.0
34 Ammonia 30% 430.0
35 Soda ash 185.0
36 MIBK 1785.0
37 Methanol 4765.0
38 Carbon 20.0
39 Acetic acid 175.0
40 Ammonia 50.0
 List of Raw Materials of Ibuprofen

Qty
S.No Name of raw material (Kgs/day)
1 Mono Chloro acetic acid 11431.8
2 Iso propyl alcohol 8381.8
3 Sulphuric acid 4170.0
4 Sodium bi carbonate 822.2
5 Sodium carbonate 205.6
6 Isobutyl benzene 12884.5
7 Acetyl chloride 8530.3
8 Aluminum chloride 14641.5
9 Conc. Hcl 30% 1273.2
10 Liq Ammonia 25 % 1273.2
11 Sodium metal 3163.8
12 Isopropyl alcohol 41793.8
13 CS Lye 48% 14681.1
14 Sodium dichromate dehydrate 8796.5
15 Sulphuric acid 16204.0
16 Acetone 40741.5
17 N- Hexane 22685.6
List of Raw Materials of Dextromethorphan
Hydrobromide

Qty
S.No Name of raw material (Kgs/day)
1 2-[1-Cyclohexyl) ethylamine 784.0
2 4- Methoxy phenyl acetic acid 862.7
3 O-xylene 3136.0
4 Phosphorous oxy chloride 1027.3
5 Sodium borohydride 192.7
6 C S lye 48 % 470.7
7 Toluene 1960.0
8 (-) Mandelic acid 687.3
9 Acetone 1764.0
10 Toluene 2085.3
11 Acetone 1254.0
12 C S lye 177.3
13 Toluene 957.3
14 Caustic 210.0
15 Methyl formate 462.7
16 Methanol 509.3
17 Toluene 816.7
18 Phosphoric acid 1474.0
19 Potassium hydroxide 400.0
20 Toluene 1936.7
21 Formaldehyde (40%) 62.7
22 Formic acid 78.7
23 Toluene 752.7
24 40% Hydroboric acid 431.3
25 Activated carbon 3.3
26 Toluene 880.0
27 Conc. HCl 441.3
 List of Raw Materials of Omega-3

Qty
S.No Name of raw material (Kgs/day)
1 Sea water 15984.0
2 Dextrose 8658.0
3 Toluene 3330.0
4 Crude oil 1332.0
5 Alkali Solution 666.0